Choose the first market around your next business milestone
Deciding whether to pursue the EU or FDA first starts with the market you need to reach and the evidence you can produce. Before you commit testing spend, put your proposed claims, route assumptions, customer access and available cash in the same decision record.
For example, a credible hospital partner can make one market commercially attractive, but it does not establish your classification or remove an evidence gap. Treat regulatory feasibility and commercial demand as separate questions, then decide whether both support the same launch sequence.
This guide uses IVDs to explain the classification comparison. Its planning questions also help other device founders, but the IVDR classification discussion does not classify a non-IVD medical device.
IVD classification in the EU and FDA needs two answers
An EU class is not a shortcut to a US classification. Build each rationale from the product's intended purpose and the applicable jurisdiction's rules rather than assigning a “closest” class.
EU IVDs fall into classes A, B, C and D. The Medical Device Coordination Group explains that classification considers intended purpose and inherent risk under IVDR Article 47 and Annex VIII. Intended purpose includes the manufacturer's label, instructions, performance evaluation and promotional claims. All applicable implementing rules and classification rules need consideration. See MDCG 2020-16 rev.5, sections 3 to 3.2, printed pages 5 and 6.
That guidance gives a useful example of why purpose matters. A test intended to screen blood and tissue donations for syphilis falls under class D, rule 1; a test intended to diagnose syphilis in an individual falls under class C, rule 3(a). These are different intended purposes, not interchangeable labels for the same launch plan. The guidance is non-binding and its examples do not replace a device-specific assessment.
US regulations define Class I through general controls, Class II through special controls in addition to general controls, and Class III as the class for which premarket approval is or will be required. A classification regulation identifies the device type and its intended use. See 21 CFR 860.3, classification definitions.
| Question | EU IVD assessment | US assessment |
|---|---|---|
| What exactly will the device do? | State intended purpose, specimen, user and claims | State intended use, user and technological characteristics |
| What supports the classification? | Record each applicable Annex VIII rule and the class rationale | Record the applicable classification regulation and device-type rationale, or the unresolved classification question |
| What supports the route? | Identify the conformity-assessment route and external assessment needs for this device | Establish the submission route and check any exemption limits rather than inferring a route from class alone |
| What is still uncertain? | Name the rule interpretation or claim that needs expert assessment | Name the device-type, predicate or exemption question that needs resolution |
The table is a planning aid, not a regulatory conversion table. In the US, exemption limits can depend on intended use and technology. For example, 21 CFR 862.9 sets specific limits for clinical chemistry and clinical toxicology devices. It is not an exemption rule for every IVD.
Where no legally marketed device supports a substantial-equivalence review and the device meets Class I or II criteria, the De Novo process may be relevant. It can follow a not-substantially-equivalent determination or a direct request when no legally marketed predicate exists. See 21 CFR 860.200. Do not assume that “no predicate” automatically means the device qualifies.
Compare the work remaining, not headline review times
A useful budget begins with your evidence gaps. Ask your regulatory lead to separate work you already have from work you still need, then ask the people doing that work for scope-specific estimates.
- Fix the proposed claims. Record the population, specimen, intended user, setting and clinical role. If you propose different claims in each market, make that difference explicit.
- Justify each route separately. Attach the classification rationale and unresolved questions. Do not turn an unconfirmed route into a committed launch date.
- Map evidence to requirements. Inventory existing studies and reports, then identify what each market still needs. Treat reuse as a question to assess, not a guaranteed saving.
- Price the missing work. Separate testing, study delivery, regulatory support, external assessment and internal staffing. Mark each line as a quote, an estimate or unknown, with its scope and date.
- Build a schedule around dependencies. Include preparation, study access, external availability and time to answer questions. Keep a review-stage estimate distinct from the full launch plan.
For instance, if your budget excludes access to the specimens needed for a performance study, the total is not yet decision-ready. A cheaper submission fee does not resolve that missing work. This is a planning recommendation, not a regulator-prescribed budgeting method.
Use one decision record for the same product
The following is a fictional planning example for a professionally used laboratory IVD. It shows how to handle uncertainty without inventing a classification or claiming a particular assay has an established route. It is not a customer case or a regulatory determination.
Assume the founder has an interested US laboratory, an EU research collaborator and preliminary analytical results. Neither commercial interest nor those preliminary results establish sufficient evidence for market access. The founder wants to choose which route to fund before commissioning further studies.
| Decision input | EU workstream | US workstream | Owner and next action |
|---|---|---|---|
| Intended purpose | Proposed professional laboratory use, specimen and clinical role to be fixed | Same proposed use, with any market-specific claim difference recorded | Founder and regulatory lead agree the product description before route selection |
| Classification and route | Class and Annex VIII rationale not yet established | Device type, classification and submission route not yet established | Regulatory lead prepares two supported rationales; no class conversion |
| Existing evidence | Preliminary analytical results to assess against EU needs | Same results to assess against US needs | Scientific lead maps each report to each market's evidence requirements |
| Missing evidence | Performance gaps and study access unresolved | Performance gaps and study access unresolved | Scientific lead specifies gaps and requests scoped study estimates |
| Commercial access | Research collaborator, no purchase commitment assumed | Interested laboratory, no purchase commitment assumed | Founder checks purchasing conditions and adoption requirements |
| Cash and timing | No complete quote or launch estimate | No complete quote or launch estimate | Founder obtains dated scopes, dependencies and contingency assumptions |
| Current decision | Preserve the EU option while resolving gaps | Investigate US feasibility first because of stated buyer interest | Fund the comparison, not an unverified submission plan |
The decision here is deliberately smaller than “launch in the US first”. Buyer interest gives the founder a reason to investigate the US route first, but the evidence does not yet justify committing to it.
Write down what would change that choice. In this example, a US evidence gap that the company cannot fund, or a credible EU purchase opportunity with a feasible evidence plan, would trigger reassessment. Set a review date and name the decision owner so the assumption does not silently become strategy.
Decide what to run in parallel
You can compare both markets before funding two submissions. Consider parallel classification and evidence planning when it helps you avoid commissioning a study that answers only one market's questions. Commit to parallel submission work only after checking whether you can fund and staff both workstreams.
A sequential approach may fit when one evidence gap or external dependency dominates your resources. Keep the second market's requirements visible and record which decisions would make later expansion harder. These are planning choices to discuss with your regulatory lead, not a universal FDA-first or EU-first rule.
If you already supply an IVD under a legacy arrangement, assess that situation separately from a new launch. Do not apply a headline transition deadline without checking the device's eligibility and current conditions with your regulatory lead.
Keep the next decision connected to the evidence
Use the medical-device glossary when unfamiliar terms get in the way. Once your EU plan reaches registration, the EUDAMED registration guide covers that separate workstream. Neither resource replaces the classification and route rationale for your product.
A useful strategy conversation starts with your proposed claims, existing reports and the commercial milestone you need to reach. Bring the uncertainties as well as the evidence, especially the assumption that would change your first-market choice.
Sources and further reading
- Medical Device Coordination Group, MDCG 2020-16 rev.5, September 2026. IVD classification guidance. Sections 3 to 3.2 explain intended purpose and application of classification rules. Non-binding guidance.
- US Code of Federal Regulations, 21 CFR 860.3. Classification definitions. Understand what US classes and classification regulations mean.
- US Code of Federal Regulations, 21 CFR 860.200. De Novo purpose and applicability. Check the scope of this classification process.
- US Code of Federal Regulations, 21 CFR 862.9. Limits on premarket-notification exemptions. A device-specific example for clinical chemistry and clinical toxicology devices, not a rule for every IVD.
